• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >RETRACTED: Odanacatib for the treatment of postmenopausal osteoporosis
【24h】

RETRACTED: Odanacatib for the treatment of postmenopausal osteoporosis

机译：缩回：奥达那替尼治疗绝经后骨质疏松症

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This article has been RETRACTED Introduction: The market of antiosteoporosis drugs has been declining in recent years, possibly in part due to the publicity around adverse events observed with bisphosphonates. Also, the proportion of patients with clinical fracture who receive adequate treatment remains low. Hence, there are still unmet needs in this field. Odanacatib is a cathepsin K inhibitor currently being developed for the treatment of postmenopausal osteoporosis that could be an advance in this context. Area covered: Odanacatib is a bone resorption inhibitor, but it preserves some degree of bone formation, which differentiates this new family of drugs from existing therapies. Odanacatib increases bone mineral density (BMD) at the spine and hip, improves bone strength estimated using finite element analysis (FEA) at the spine and hip as well as at the distal tibia and radius. The safety profile has been satisfactory so far. A robust antifracture efficacy has been announced when the Phase III pivotal trial had been terminated after interim analysis, but we do not yet have access to the complete results. Expert opinion: Odanacatib may have an important role in future guidelines if it provides a substantial advantage compared to the effective and inexpensive current generic drugs, in terms of antifracture efficacy or safety.
机译：简介：近年来，抗骨质疏松药物的市场一直在下降，这可能部分是由于有关双膦酸盐类药物不良反应的宣传。同样，接受适当治疗的临床骨折患者比例仍然很低。因此，该领域仍然存在未满足的需求。 Odanacatib是一种组织蛋白酶K抑制剂，目前正在开发中，用于治疗绝经后骨质疏松症，这在此方面可能是一个进步。覆盖区域：Odanacatib是一种骨吸收抑制剂，但保留了一定程度的骨形成，从而使这种新的药物家族与现有疗法有所区别。 Odanacatib增加了脊柱和髋部的骨矿物质密度（BMD），提高了使用有限元分析（FEA）估算的脊柱和髋部以及胫骨远端和radius骨的骨强度。到目前为止，安全性令人满意。在中期分析后终止第三阶段的关键试验时，已经宣布了强有力的抗骨折疗效，但我们尚无法获得完整的结果。专家意见：如果奥达那卡素在抗骨折功效或安全性方面与有效且便宜的现有非专利药相比具有实质性优势，则它可能在未来的指南中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号